The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against NutraCea

NEW YORK, March 6, 2009 (LAWFUEL) — The Brualdi Law Firm, P.C.
announces that a lawsuit has been commenced in the United States
District Court for the District of Arizona on behalf of all purchasers
of NutraCea common stock (OTCBB:NTRZ) during the period from August 14,
2007 through and including February 23, 2009 (the “Class Period”) for
violations of the federal securities laws.

No class has yet been certified in the above action. Until a class is
certified, you are not represented by counsel unless you retain one. If
you purchased NutraCea common stock during the Class Period, and wish
to move the court for appointment of lead plaintiff, you must do so by
April 28, 2009. A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. The lead
plaintiff will be selected from among applicants claiming the largest
loss from investment in the Company during the Class Period. You do not
need to seek appointment as a lead plaintiff in order to share in any

To be a member of the class you need not take any action at this time,
and you may retain counsel of your choice. If you wish to discuss this
action or have any questions concerning this Notice or your rights or
interests with respect to these matters, please contact Sue Lee at The
Brualdi Law Firm, P.C. 29 Broadway, Suite 2400, New York, New York
10006, by telephone toll free at (877) 495-1187 or (212) 952-0602, by
email to [email protected] or visit our website at

The complaint charges NutraCea and certain of its officers and
directors with violations of Section 10(b) and Section 20(a) of the
Securities Exchange Act of 1934 by issuing materially inaccurate
financial statements to the investing public. On February 23, 2009,
NutraCea announced that it would be restating revenue for the quarterly
periods from the second quarter of 2007 through the fourth quarter of
2008 and for the fiscal year ended December 31, 2007. The restatement
is due to NutraCea’s improper recognition of revenue on two
transactions in 2007. Of the approximately $22.2 million of revenue
reported for 2007, NutraCea estimates that $4.6 million will be
reversed. News of the pending restatement caused NutraCea’s stock price
to fall significantly, damaging investors.

Scroll to Top